The purpose of this study is to see how effective 2 drugs, irbesartan and pravastatin, are at
slowing kidney transplant failure.
Many kidney transplant patients have some type of chronic rejection. Chronic rejection is a
disease that causes scarring and damage to the kidney. Over time, chronic rejection can lead
to kidney failure, making it necessary for patients to start dialysis and possibly receive
another kidney transplant. Doctors would like to see whether irbesartan and pravastatin can
slow this damage and prevent kidney failure in patients with signs of chronic rejection.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)